ViiV/GSK HIV med Tivicay wins early FDA OK
This article was originally published in Scrip
Executive Summary
Watch out Gilead and Merck. There's a new competitor seeking to take a share of the HIV treatment market, with ViiV Healthcare winning an earlier-than-expected OK from the US FDA on 12 August for the company's Tivicay (dolutegravir), an oral integrase strand transfer inhibitor (ISTI).